Skip to main content
. 2019 Jul 1;3(13):1950–1960. doi: 10.1182/bloodadvances.2019000030

Table 2.

Univariate analysis of outcomes based on patient, disease, and transplant characteristics

RI NRM LFS OS GRFS aGVHD grade II-IV aGVHD grade III-IV cGVHD Extensive cGVHD
2-y outcomes
 No ATG 25.1 (21.1-29.3) 16 (12.8-19.6) 58.9 (54.2-63.5) 63.7 (59.1-68.2) 40.9 (36.2-45.6) 33 (28.7-37.4) 13 (10.1-16.2) 46.2 (41.3-51) 22.3 (18.5-26.4)
 ATG 26.1 (20.6-31.9) 16.7 (12.2-21.7) 57.2 (50.9-63.6) 62.4 (56.1-68.6) 43.3 (36.8-49.8) 24.1 (18.8-29.7) 7 (4.2-10.6) 34.3 (28.1-40.6) 16.4 (11.9-21.5)
5-y outcomes
 No ATG 29.1 (24.8-33.6) 18.5 (14.9-22.4) 52.4 (47.5-57.3) 55.1 (50.1-60) 33.2 (28.5-37.9) 33 (28.7-37.4) 13 (10.1-16.2) 51.5 (46.4-56.3) 27.3 (23-31.8)
 ATG 31.6 (25.4-38) 18 (13.3-23.3) 50.4 (43.6-57.2) 54 (47.1-61) 38.4 (31.8-45) 24.1 (18.8-29.7) 7 (4.2-10.6) 36.8 (30.3-43.2) 18.3 (13.4-23.8)
P .78 .98 .74 .74 .28 .01 .01 <.01 .02
Age
 Younger than median 29.8 (24.7-35) 16.5 (12.7-20.8) 53.7 (48.1-59.4) 56.5 (50.7-62.2) 35.9 (30.4-41.4) 33.7 (28.7-38.8) 12.6 (9.3-16.3) 45.5 (39.8-51.1) 25.8 (21.1-30.8)
 Older than median 30.1 (25.1-35.2) 20.1 (15.9-24.7) 49.8 (44.2-55.4) 52.9 (47.2-58.5) 34 (28.6-39.4) 26.3 (21.8-31.1) 9.2 (6.5-12.5) 47.4 (41.6-52.9) 22.7 (18.1-27.6)
P .60 .27 .18 .14 .41 .04 .10 .71 .41
Disease status at allo-HCT
 CR1 28 (23.7-32.4) 17.7 (14.3-21.5) 54.3 (49.5-59.2) 57.1 (52.2-62.1) 37.1 (32.3-41.9) 29.8 (25.7-33.9) 10.8 (8.2-13.8) 49.7 (44.7-54.4) 25.1 (21-29.5)
 CR2+ 23.7 (16.8-31.3) 21.1 (14.6-28.4) 55.2 (46.6-63.7) 59.4 (50.8-68) 36.8 (28.4-45.2) 24.6 (17.5-32.2) 10 (5.7-15.6) 41.3 (32.6-49.9) 26.1 (18.8-34)
 Advanced 52.2 (39.6-63.3) 16.7 (9.6-25.5) 31.2 (20.1-42.3) 32.9 (21.8-43.9) 19.1 (9.3-28.9) 39.8 (29.2-50.1) 12.9 (6.8-21) 36.1 (25-47.3) 16.2 (9-25.2)
P <.01 .70 <.01 <.01 <.01 .04 .64 .07 .52
Cytogenetics
 Good 18.9 (12.3-26.7) 19 (12.4-26.7) 62.1 (53-71.1) 65.3 (56.2-74.3) 40.4 (31.1-49.8) 26.4 (18.8-34.7) 11 (6.3-17.1) 47.5 (37.8-56.6) 29.8 (21.4-38.6)
 Intermediate 25.8 (21.3-30.6) 17.8 (14-22) 56.4 (51.1-61.7) 60 (54.7-65.3) 38 (32.7-43.2) 32.2 (27.6-36.9) 10.9 (8.1-14.3) 51 (45.5-56.2) 26.3 (21.6-31.2)
 Poor 46.1 (38.4-53.4) 18.8 (13.3-25) 35.1 (27.8-42.5) 36.8 (29.1-44.5) 24.5 (17.8-31.2) 27.4 (21.1-34.1) 10.7 (6.8-15.6) 35.7 (28.3-43.1) 16.5 (11.3-22.5)
P <.01 .99 <.01 <.01 <.01 .29 1.0 .02 .03
KPS at allo-HCT
 <90% 30.1 (22.4-38.2) 26.7 (19.4-34.4) 43.2 (34.6-51.8) 43.5 (34.7-52.3) 29.4 (21.4-37.5) 31.9 (24.3-39.8) 11.4 (6.8-17.4) 45.7 (36.2-54.6) 23.6 (16.6-31.4)
 ≥90% 30.1 (25.9-34.4) 16.5 (13.3-20) 53.4 (48.7-58) 57.1 (52.4-61.7) 36.5 (32-41) 28.5 (24.6-32.4) 10.2 (7.8-13) 47.6 (42.9-52.1) 24.7 (20.8-28.8)
P .57 .01 .01 <.01 .02 .38 .77 .40 .92
Donor type
 MSD 31.8 (26.9-36.7) 15.1 (11.6-19.1) 53.1 (47.8-58.4) 56.4 (51-61.8) 34 (28.8-39.1) 25.8 (21.6-30.2) 9.6 (7-12.7) 49.7 (44.2-54.9) 27.5 (22.7-32.4)
 UD 10/10 (HLA) 28.9 (22.9-35.2) 22.3 (17-28.2) 48.8 (41.9-55.7) 51.1 (44-58.3) 36.7 (29.9-43.5) 36.6 (30.2-42.9) 11.5 (7.7-16) 41.1 (34.2-47.8) 19.9 (14.7-25.7)
 UD 9/10 (HLA) 23.8 (14.5-34.4) 23.4 (14.3-33.9) 52.8 (41-64.6) 56.1 (44.6-67.6) 33.3 (22.1-44.5) 33.3 (22.5-44.6) 16.2 (8.9-25.5) 46.3 (33.7-58) 21.7 (12.7-32.3)
P .32 .03 .56 .42 .44 .01 .23 .40 .09
Graft source
 BM 19.4 (13.2-26.3) 18.4 (12.5-25.2) 62.3 (54.2-70.3) 65.6 (57.5-73.7) 44.5 (36.1-52.9) 36.5 (28.5-44.5) 10.6 (6.2-16.4) 45.2 (36.5-53.5) 21.5 (15-28.8)
 PB 33 (28.8-37.2) 18.4 (15.1-22) 48.6 (44.1-53.2) 51.5 (46.9-56.1) 32.2 (27.8-36.5) 28.3 (24.6-32.2) 11 (8.5-13.7) 47.1 (42.4-51.5) 25.1 (21.2-29.1)
P .01 .99 .02 .01 .02 .14 .79 .92 .28

Other than P values, data are % (95% CI).